Cotellic and Skin toxicity - a phase IV clinical study of FDA data

Summary:

Skin toxicity is reported as a side effect among people who take Cotellic (cobimetinib fumarate), especially for people who are female, 60+ old, also take Zelboraf, and have Metastatic malignant melanoma.

The phase IV clinical study analyzes which people have Skin toxicity when taking Cotellic. It is created by eHealthMe based on reports of 1,908 people who have side effects when taking Cotellic from the FDA, and is updated regularly.

What is Cotellic?

Cotellic has active ingredients of cobimetinib fumarate. eHealthMe is studying from 1,908 Cotellic users. Check the latest studies of Cotellic.

What is Skin toxicity?

Skin toxicity (skin damage due to toxin/poison) is found to be associated with 267 drugs and 378 conditions by eHealthMe. Check the latest studies of Skin toxicity.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 27, 2026

1,908 people reported to have side effects when taking Cotellic.
Among them, 20 people (1.05%) have Skin toxicity.

Among these 20 people:

What is the gender of people who have Skin toxicity when taking Cotellic? *

female: 52.94 %
male: 47.06 %

What is the age of people who have Skin toxicity when taking Cotellic? *

What are other drugs people take besides Cotellic? *

Zelboraf: 16 people, 80.00%
Tecentriq: 1 person, 5.00%
Tafinlar: 1 person, 5.00%
Mekinist: 1 person, 5.00%

What are other side effects people have besides Skin toxicity? *

Fever: 3 people, 15.00%
Itching: 2 people, 10.00%
Rashes (redness): 2 people, 10.00%
Photosensitivity Reaction: 2 people, 10.00%
Blood Creatinine Increased: 1 person, 5.00%
Diarrhea: 1 person, 5.00%
Dry Mouth: 1 person, 5.00%
Dry Skin: 1 person, 5.00%
Erythema Multiforme (a type of hypersensitivity reaction): 1 person, 5.00%
Feeling Hot: 1 person, 5.00%

What are the existing conditions these people have? *

Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 6 people, 30.00%
Malignant Melanoma (skin cancer rises from melancytes): 5 people, 25.00%
Superficial Spreading Melanoma Stage Unspecified (superficial spreading cancer stage unspecified): 1 person, 5.00%
Malignant Melanoma Stage Iv (the cancer has spread to other places in the body, such as the lung, liver, brain, bone, soft tissue, or gastrointestinal (gi) tract. cancer may have spread to places in the skin far away from where it first started): 1 person, 5.00%
Adenocarcinoma (malignant tumour formed from glandular structures in epithelial tissue): 1 person, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Cotellic and have Skin toxicity?

- Check whether Skin toxicity is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cotellic:

Cotellic (1,908 reports)

Skin toxicity treatments and more:

Skin toxicity (5,295 reports)

Browse all side effects of Cotellic:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Skin toxicity:

Skin toxicity (267 drugs)

Browse all the conditions that are associated with Skin toxicity:

Skin toxicity (378 conditions)

Related publications that referenced our studies

Kim DJ, Lee SC, Park GS, Kim GJ, Hwang WT, Lee CS, Lee MH, Hahn DH, Koh HC, "Amiodarone Induced Multiorgan Toxicity in a Patient of Hypertrophic Cardiomyopathy With Atrial Fibrillation", Journal of the Korean Geriatrics Society, 2013 Dec .
Kim DJ, Lee SC, Park GS, Kim GJ, Hwang WT, Lee CS, Lee MH, Hahn DH, Koh HC, "Amiodarone Induced Multiorgan Toxicity in a Patient of Hypertrophic Cardiomyopathy With Atrial Fibrillation", Journal of the Korean Geriatrics Society, 2013 Dec .

How the study uses the data?

The study uses data from the FDA. It is based on cobimetinib fumarate (the active ingredients of Cotellic) and Cotellic (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.